{"id":79412,"date":"2026-09-08T12:44:31","date_gmt":"2026-09-08T04:44:31","guid":{"rendered":"https:\/\/flcube.com\/?p=79412"},"modified":"2026-09-08T12:44:32","modified_gmt":"2026-09-08T04:44:32","slug":"eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s","status":"publish","type":"post","link":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/","title":{"rendered":"Eton Pharmaceuticals Licenses Auson&#8217;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Auson Pharma (US)<\/strong>, a wholly\u2011owned subsidiary of <strong>Shanghai Auson Pharmaceuticals<\/strong>, announced on <strong>August 6, 2026<\/strong> that it has signed an <strong>exclusive licensing agreement<\/strong> with <strong>Eton Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ETON:NASDAQ\">NASDAQ: ETON<\/a>), granting the latter the rights to <strong>develop and commercialize timolol gel (ASN001)<\/strong> in the <strong>North American market<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-milestone\" class=\"wp-block-heading\">Deal Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Auson Pharma (US) \u2014 wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Eton Pharmaceuticals, Inc. (NASDAQ: ETON)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td><strong>ASN001<\/strong> \u2014 innovative topical timolol gel<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td><strong>Infantile hemangioma<\/strong><\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td><strong>North America<\/strong><\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive development and commercialization<\/td><\/tr><tr><td><strong>Signing Date<\/strong><\/td><td>6 Aug 2026<\/td><\/tr><tr><td><strong>Regulatory Plan<\/strong><\/td><td><strong>NDA submission to the U.S. FDA in H2 2027<\/strong>; approval expected in <strong>2028<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-formulation\" class=\"wp-block-heading\">Product Profile &amp; Formulation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> Innovative <strong>topical gel formulation of timolol<\/strong>, a beta\u2011blocker with established use in vascular lesions<\/li>\n\n\n\n<li><strong>Formulation Differentiator:<\/strong> Contains <strong>no transdermal enhancers<\/strong>, specifically designed to localize drug activity at the lesion while minimizing systemic absorption<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> <strong>Infants<\/strong> with infantile hemangioma \u2014 a population where systemic exposure safety margins are critical<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-pivotal-registration-studies\" class=\"wp-block-heading\">Clinical Evidence \u2013 Pivotal Registration Studies<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>12\u2011Week Steady\u2011State Median Plasma Concentration (TID dosing)<\/strong><\/td><td><strong>109 pg\/mL<\/strong><\/td><td>Substantially lower than systemic exposure following ocular administration of timolol eye drops<\/td><\/tr><tr><td><strong>12\u2011Week Steady\u2011State Median Plasma Concentration (BID dosing)<\/strong><\/td><td><strong>72.7 pg\/mL<\/strong><\/td><td>Further reduced exposure with twice\u2011daily regimen<\/td><\/tr><tr><td><strong>Overall Profile<\/strong><\/td><td>Favorable safety alongside <strong>excellent efficacy<\/strong><\/td><td>Pivotal registration studies completed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-regulatory-timeline-amp-first-mover-potential\" class=\"wp-block-heading\">Regulatory Timeline &amp; First\u2011Mover Potential<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Timing<\/th><\/tr><\/thead><tbody><tr><td><strong>NDA submission (U.S. FDA)<\/strong><\/td><td><strong>Second half of 2027<\/strong><\/td><\/tr><tr><td><strong>Expected approval<\/strong><\/td><td><strong>2028<\/strong><\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>Potential <strong>first topical formulation approved<\/strong> for the treatment of infantile hemangioma in the United States<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need in Pediatric Dermatology:<\/strong> Infantile hemangioma is the most common benign tumor of infancy; current U.S. treatment relies on oral propranolol, which carries systemic beta\u2011blockade risks in infants. A topical, enhancer\u2011free formulation addresses a significant safety gap.<\/li>\n\n\n\n<li><strong>First\u2011to\u2011Market Opportunity:<\/strong> No topical formulation is currently approved in the U.S. for infantile hemangioma \u2014 approval of ASN001 would establish a new product category.<\/li>\n\n\n\n<li><strong>Portfolio Fit for Eton:<\/strong> The license adds a differentiated pediatric dermatology asset to Eton Pharmaceuticals&#8217; rare\u2011disease and specialty portfolio, with a defined regulatory runway to 2028.<\/li>\n\n\n\n<li><strong>Global Strategy for Auson:<\/strong> The North American out\u2011licensing extends Shanghai Auson Pharmaceuticals&#8217; international footprint, pairing its China\u2011developed asset with an established U.S. commercial platform.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NDA submission timing, FDA approval, and commercialization of ASN001. Actual results may differ due to risks including regulatory review outcomes, manufacturing scale\u2011up, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4935,16,4936,4937],"class_list":["post-79412","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auson-pharmaceuticals","tag-cancer","tag-eton-pharmaceuticals","tag-nasdaq-eton"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eton Pharmaceuticals Licenses Auson&#039;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S. - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eton Pharmaceuticals Licenses Auson&#039;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S.\" \/>\n<meta property=\"og:description\" content=\"Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T04:44:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-08T04:44:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eton Pharmaceuticals Licenses Auson&#8217;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S.\",\"datePublished\":\"2026-09-08T04:44:31+00:00\",\"dateModified\":\"2026-09-08T04:44:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/\"},\"wordCount\":435,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auson Pharmaceuticals\",\"Cancer\",\"Eton Pharmaceuticals\",\"NASDAQ: ETON\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/\",\"name\":\"Eton Pharmaceuticals Licenses Auson's Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S. - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-08T04:44:31+00:00\",\"dateModified\":\"2026-09-08T04:44:32+00:00\",\"description\":\"Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eton Pharmaceuticals Licenses Auson&#8217;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/author\\\/wesley\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eton Pharmaceuticals Licenses Auson's Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S. - Insight, China&#039;s Pharmaceutical Industry","description":"Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/","og_locale":"en_US","og_type":"article","og_title":"Eton Pharmaceuticals Licenses Auson's Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S.","og_description":"Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.","og_url":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-08T04:44:31+00:00","article_modified_time":"2026-09-08T04:44:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/#article","isPartOf":{"@id":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eton Pharmaceuticals Licenses Auson&#8217;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S.","datePublished":"2026-09-08T04:44:31+00:00","dateModified":"2026-09-08T04:44:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/"},"wordCount":435,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auson Pharmaceuticals","Cancer","Eton Pharmaceuticals","NASDAQ: ETON"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/","url":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/","name":"Eton Pharmaceuticals Licenses Auson's Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S. - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-08T04:44:31+00:00","dateModified":"2026-09-08T04:44:32+00:00","description":"Auson Pharma (US), a wholly\u2011owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.","breadcrumb":{"@id":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eton Pharmaceuticals Licenses Auson&#8217;s Timolol Gel ASN001 for North America \u2013 Potential First Topical Therapy for Infantile Hemangioma in the U.S."}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/author\/wesley\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/comments?post=79412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79412\/revisions"}],"predecessor-version":[{"id":79414,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79412\/revisions\/79414"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/media?parent=79412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/categories?post=79412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/tags?post=79412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}